CareDx has agreed to acquire Naveris in a deal worth up to $260m, priming the company to inherit a blood‑based monitoring solution for viral‑mediated cancers.
CareDx’s deal for the precision oncology diagnostics company is structured with an upfront cash payment of $160m, with the potential for an additional $100m pending revenue milestones. CareDx and Naveris expect the transaction to close in Q3 2026.
Naveris’s lead product is NavDx, a liquid biopsy platform based on tumour tissue modified viral (TTMV) DNA. The test measures fragments of viral DNA released from tumour tissue into the bloodstream and serves as a biomarker in human papillomavirus (HPV)‑driven cancers.
Designed for tumour‑naïve testing and patient management from diagnosis through post‑treatment molecular residual disease (MRD) surveillance, NavDx obtained Medicare coverage in 2023. According to Naveris, the Massachusetts-based company has performed 130,000 commercial tests with NavDx to date.
In CareDx’s Q1 2026 financials, released on 28 April, the company’s testing services segment reported revenue of $91m, corresponding to a 48% year-over-year (YoY) uptick. CareDx reported revenue of $16m for its patient and digital solutions segment versus $12m in the same period of 2025.
Meanwhile, CareDx announced plans to divest its lab products business to EuroBio Scientific in a $170m deal on 15 April. In Q1, CareDx said this segment was “relatively flat”, declining by 4% YoY to $10m.
CareDx’s decision to sell its lab products business follows a similar move by Thermo Fisher this week to sell its microbiology business to Astorg in a deal above $1bn, suggesting a trend of strategic realignment for some players involved in the diagnostics space.
CareDx CEO John Hanna anticipates that the acquisition of Naveris will accelerate its strategy to advance the growth of its precision medicine testing services and patient and digital solutions business segments.
Commenting on the deal, Hanna said: “We are focused on being a leader in concentrated speciality markets where a high burden of disease drives repeat testing. Naveris fits that profile with a differentiated technology that is early in its adoption.
“Naveris is poised for strong growth, leveraging our core capabilities – building belief in molecular testing, simplifying clinical workflow, and generating evidence for coverage and reimbursement.”
Naveris CEO, James McNally, commented: “We are thrilled to be combining forces with CareDx to fulfil our mission of improving patient outcomes by delivering disruptive technology that transforms cancer care and expanding patient access to precision medicine.”
